Table 1.

Recently-published articles on management of MVA.

Study	Design	Treatment	Duration	Results	Ref
Henry et al. [206]	Pilot clinical trial	Autologous CD34+ stem cell therapy	180 days	(i) Improved coronary flow reserve (2.08 ± 0.32 changed to 2.68 ± 0.79; p < 0.005) (ii) Decreased angina frequency (p < 0.004) (iii) Improved Canadian cardiovascular society class (p < 0.001) (iv) Improved quality of life (p ≤ 0.04)	[206]
Zhang et al. [55]	RCT	Group 1: fluvastatin (statin; 40 mg daily) Group 2: diltiazem (CCB; 90 mg daily) Group 3: statin and CCB	90 days	(i) Improved coronary flow reserve (23.2%, 12.4%, and 29.1% in groups 1 to 3, respectively; p < 0.05) (ii) Increased time to 1 mm ST segment depression (241 ± 97 to 410 ± 140 s, p < 0.05 in group 1; 258 ± 91 to 392 ± 124 s, p < 0.05 in group 2, and 250 ± 104 to 446 ± 164 s, p < 0.05 in group 3)	[55]
Kabaklić et al. [207]	Pilot RCT	Atorvastatin (20 mg daily)	90 and 180 days	(i) Improved flow-mediated dilation (p < 0.001 for 90 and 180 days) (ii) No difference in reactive hyperemia index (iii) Insignificant improvement in rate-normalized augmentation index (p = 0.077)	[207]
Makarewicz-Wujec et al. [208]	RCT	DASH diet	12 months	(i) Insignificant reduction in RANTES (42.7 ± 21.1 to 38.1 ± 18.5, p = 0.134) (ii) Reduced CXCL4 (12.38 ± 4.1 to 8.36 ± 2.3, p < 0.001)	[208]

Ref: reference; RCT: randomized controlled trial; CCB: calcium channel blocker; DASH: dietary approaches to stop hypertension.